Anti-Asthmatics And COPD Drugs Global Market Report 2025

Description

Anti-asthmatic and chronic obstructive pulmonary disease (COPD) drugs are medications designed to alleviate the frequency of acute attacks in conditions such as asthma, emphysema, chronic bronchitis, and nocturnal awakenings.

The primary classes of drugs in anti-asthmatics and COPD include bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination drugs. Bronchodilators stimulate the bronchi and bronchioles, reducing respiratory airway resistance and enhancing lung airflow. Various types of bronchodilators include anti-histamine drugs, long-acting B2-agonists (LABA), inhaled corticosteroids, short-acting muscarinic receptor antagonists (Samas), and other combinations of anti-asthmatics and COPD drugs. These medications are utilized by asthma and COPD patients and are distributed through diverse channels such as hospital pharmacies, private clinics, drug stores, retail pharmacies, and e-commerce platforms.

The anti-asthmatics and chronic obstructive pulmonary disease (COPD) market research report are one of a series of new reports from The Business Research Company that provides anti-asthmatics and chronic obstructive pulmonary disease (COPD) market statistics, including anti-asthmatics and chronic obstructive pulmonary disease (COPD) industry global market size, regional shares, competitors with an anti-asthmatics and chronic obstructive pulmonary disease (COPD) market share, detailed anti-asthmatics and chronic obstructive pulmonary disease (COPD) market segments, market trends and opportunities, and any further data you may need to thrive in the anti-asthmatics and chronic obstructive pulmonary disease (COPD) industry. These anti-asthmatics and chronic obstructive pulmonary disease (COPD) market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-asthmatics and COPD drugs market size has grown strongly in recent years. It will grow from $80.82 billion in 2024 to $86.11 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to include increased prevalence of respiratory diseases, increased incidence of tobacco smoking, global warming, geriatric population, emerging markets, new methods for drug discovery, and rise in healthcare expenditure.

The anti-asthmatics and COPD drugs market size is expected to see strong growth in the next few years. It will grow to $107.01 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to the increased popularity of e-cigarettes/ vaping, rising obesity levels, technology, a large pool of undiagnosed population, use of anti-asthmatics and COPD drugs to treat COVID-19 patients, and increasing consumption of fats. Major trends in the forecast period include developing probiotic drugs for asthma, developing anti-il-5 drugs to expand their business portfolio, launching new innovative products to focus on establishing their market position and sustaining their position among the intense competition in the market, investing more in developing bioelectric medicines, focus on increasing the number of collaborations, providing customized treatments, and developing combination drugs to offer better result, developing biologics to capitalize on the growing demand for biologics.

Modifiable risk factors such as smoking, sedentary lifestyles, and unhealthy dietary habits significantly contribute to driving the anti-asthmatics and copd drugs market. While smoking rates are declining globally, certain developing nations such as China, India, Indonesia, and Nigeria are witnessing an upward trend in smoking prevalence. For example, Indonesia is anticipated to see a rise of 24 million tobacco smokers by 2025, while Nigeria is expected to witness an increase of 7 million smokers. Additionally, China holds over 40% of global cigarette consumption. Unhealthy dietary practices, especially high consumption of fats and saturated fatty acids prevalent in high-income countries such as the USA and Europe, contribute to the risk factors associated with Asthma and COPD. WHO data highlights that in developed countries, over 35% of energy intake comes from fats, in contrast to less than 20% in low-income countries and below 25% in lower-middle-income countries.

The prevalence of asthmatic disorders is anticipated to be a driving force behind the growth of the anti-asthmatics and COPD drugs market. Asthma, a chronic condition characterized by airway inflammation and constriction, has shown an upward trend in cases, prompting the identification and development of new medications to manage these disorders. For example, based on data from the National Health Interview Survey (NHIS) in April 2022, approximately 42.7% of children aged 18 or younger and 52.9% of children under 5 years old were reported to have asthma in the United States in 2020. This rise in asthmatic cases is expected to stimulate the continuous development of innovative drugs, further propelling the anti-asthmatics and copd drugs market.

Numerous inhalers devoid of chlorofluorocarbons (CFCs) are presently accessible for managing asthma and chronic obstructive pulmonary disease (COPD). While these products might not be formally designated as direct replacements for CFC Metered Dose Inhalers, they can be considered beneficial medications for many patients, potentially eliminating the necessity for specific CFC Metered Dose Inhalers. The determination of official alternatives will be made by the FDA, employing criteria established via notice-and-comment rulemaking processes.

Major players within the anti-asthmatics and COPD drugs market are driving innovation with products such as the dose combination (FDC) drug, Indacaterol plus Mometasone, aiming to enhance their market position. This FDC medication, administered via the Breezhaler device, represents a once-daily treatment designed for ongoing asthma management in patients. Glenmark Pharmaceuticals, for instance, introduced the novel FDC drug named Indamet in India in June 2022. Available in three variations, Indamet maintains a consistent dose of 150 mcg of Indacaterol while varying Mometasone doses (80 mcg, 160 mcg, and 320 mcg strengths) to address uncontrollable asthma cases.

The trend toward combination therapies for asthma and COPD treatment is on the rise, showcasing greater efficacy in patient-reported outcomes (PROs) compared to monotherapies. Combinations such as short-acting beta-agonists (SABA) coupled with short-acting muscarinic antagonists (SAMA) have demonstrated superior effects on lung function when compared to individual medications. Similarly, the utilization of long-acting beta-agonists (LABA) paired with long-acting muscarinic antagonists (LAMA) has shown improved lung function in comparison to long-acting monotherapy bronchodilators.

Major companies operating in the anti-asthmatics and COPD drugs market include GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Sumitomo Dainippon Pharma Co. Ltd., China National Pharmaceutical Group Co. Ltd. (Sinopharm), Shanghai Acebright Pharmaceuticals Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd, Hanmi Pharmaceutical, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd, Shanghai Anovent Pharma, China Meheco Group Co. Ltd., Lupin Limited, ASGEN Pharmaceutical Co. Ltd, Abbott Laboratories, Pfizer, Vectura Group, Bristol Myers Squibb, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Bayer, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Aspen Nigeria

North America was the largest region in the anti-asthmatics and COPD drugs market in 2024. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and COPD drugs market during the forecast period. The regions covered in the anti-asthmatics and COPD drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anti-asthmatics and COPD drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The anti-asthmatic and chronic obstructive pulmonary disease market consists of corticosteroid, bronchodilator, fluticasone and salmeterol. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anti-Asthmatics And COPD Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-asthmatics and copd drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anti-asthmatics and copd drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anti-asthmatics and copd drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, Combination Drugs
2) By Distribution Channel: Hospital Pharmacies, General Pharmacies, Online Retailers
3) By End User: Asthma Patients, COPD Patients
4) By Therapy: Preventive, Curative
5) By Route Of Administration: Oral, Inhaled, Intravenous, Subcutaneous
6) By Age Group: Below 5, 5-14, 15-60, Above 60
Subsegments:
1) By Bronchodilators: Short-Acting Beta-Agonists (SABAs); Long-Acting Beta-Agonists (LABAs); Anticholinergics (Short-Acting And Long-Acting); Methylxanthines
2) By Anti-Inflammatory Drugs: Corticosteroids (Inhaled And Systemic); Leukotriene Modifiers; Phosphodiesterase-4 Inhibitors
3) By Monoclonal Antibodies: Anti-IgE Antibodies; Anti-IL-5 Antibodies; Anti-IL-4 Or IL-13 Antibodies
4) By Combination Drugs: Combination Bronchodilator Inhalers (LABA + LAMA); Inhaled Corticosteroid + Long-Acting Beta-Agonist (ICS + LABA)
Companies Mentioned: GlaxoSmithKline plc; AstraZeneca plc; Boehringer Ingelheim GmbH; F. Hoffmann-La Roche Ltd.; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r25456

1. Executive Summary

2. Anti-Asthmatics And COPD Drugs Market Characteristics

3. Anti-Asthmatics And COPD Drugs Market Trends And Strategies

4. Anti-Asthmatics And COPD Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Anti-Asthmatics And COPD Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Anti-Asthmatics And COPD Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Anti-Asthmatics And COPD Drugs Market Growth Rate Analysis
5.4. Global Anti-Asthmatics And COPD Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Anti-Asthmatics And COPD Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Anti-Asthmatics And COPD Drugs Total Addressable Market (TAM)

6. Anti-Asthmatics And COPD Drugs Market Segmentation

6.1. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bronchodilators
Anti-Inflammatory Drugs
Monoclonal Antibodies
Combination Drugs
6.2. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
General Pharmacies
Online Retailers
6.3. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Asthma Patients
COPD Patients
6.4. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Preventive
Curative
6.5. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Inhaled
Intravenous
Subcutaneous
6.6. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Below 5
5/14/2024
15-60
Above 60
6.7. Global Anti-Asthmatics And COPD Drugs Market, Sub-Segmentation Of Bronchodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Short-Acting Beta-Agonists (SABAs)
Long-Acting Beta-Agonists (LABAs)
Anticholinergics (Short-Acting And Long-Acting)
Methylxanthines
6.8. Global Anti-Asthmatics And COPD Drugs Market, Sub-Segmentation Of Anti-Inflammatory Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Corticosteroids (Inhaled And Systemic)
Leukotriene Modifiers
Phosphodiesterase-4 Inhibitors
6.9. Global Anti-Asthmatics And COPD Drugs Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anti-IgE Antibodies
Anti-IL-5 Antibodies
Anti-IL-4 Or IL-13 Antibodies
6.10. Global Anti-Asthmatics And COPD Drugs Market, Sub-Segmentation Of Combination Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Combination Bronchodilator Inhalers (LABA + LAMA)
Inhaled Corticosteroid + Long-Acting Beta-Agonist (ICS + LABA)

7. Anti-Asthmatics And COPD Drugs Market Regional And Country Analysis

7.1. Global Anti-Asthmatics And COPD Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Anti-Asthmatics And COPD Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anti-Asthmatics And COPD Drugs Market

8.1. Asia-Pacific Anti-Asthmatics And COPD Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anti-Asthmatics And COPD Drugs Market

9.1. China Anti-Asthmatics And COPD Drugs Market Overview
9.2. China Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anti-Asthmatics And COPD Drugs Market

10.1. India Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anti-Asthmatics And COPD Drugs Market

11.1. Japan Anti-Asthmatics And COPD Drugs Market Overview
11.2. Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anti-Asthmatics And COPD Drugs Market

12.1. Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anti-Asthmatics And COPD Drugs Market

13.1. Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anti-Asthmatics And COPD Drugs Market

14.1. South Korea Anti-Asthmatics And COPD Drugs Market Overview
14.2. South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anti-Asthmatics And COPD Drugs Market

15.1. Western Europe Anti-Asthmatics And COPD Drugs Market Overview
15.2. Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anti-Asthmatics And COPD Drugs Market

16.1. UK Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anti-Asthmatics And COPD Drugs Market

17.1. Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anti-Asthmatics And COPD Drugs Market

18.1. France Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anti-Asthmatics And COPD Drugs Market

19.1. Italy Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anti-Asthmatics And COPD Drugs Market

20.1. Spain Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anti-Asthmatics And COPD Drugs Market

21.1. Eastern Europe Anti-Asthmatics And COPD Drugs Market Overview
21.2. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anti-Asthmatics And COPD Drugs Market

22.1. Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anti-Asthmatics And COPD Drugs Market

23.1. North America Anti-Asthmatics And COPD Drugs Market Overview
23.2. North America Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anti-Asthmatics And COPD Drugs Market

24.1. USA Anti-Asthmatics And COPD Drugs Market Overview
24.2. USA Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anti-Asthmatics And COPD Drugs Market

25.1. Canada Anti-Asthmatics And COPD Drugs Market Overview
25.2. Canada Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anti-Asthmatics And COPD Drugs Market

26.1. South America Anti-Asthmatics And COPD Drugs Market Overview
26.2. South America Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anti-Asthmatics And COPD Drugs Market

27.1. Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anti-Asthmatics And COPD Drugs Market

28.1. Middle East Anti-Asthmatics And COPD Drugs Market Overview
28.2. Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anti-Asthmatics And COPD Drugs Market

29.1. Africa Anti-Asthmatics And COPD Drugs Market Overview
29.2. Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anti-Asthmatics And COPD Drugs Market Competitive Landscape And Company Profiles

30.1. Anti-Asthmatics And COPD Drugs Market Competitive Landscape
30.2. Anti-Asthmatics And COPD Drugs Market Company Profiles
- 30.2.1. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Boehringer Ingelheim GmbH Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Anti-Asthmatics And COPD Drugs Market Other Major And Innovative Companies

31.1. Sanofi S.A.
31.2. Chiesi Farmaceutici S.p.A.
31.3. Teva Pharmaceutical Industries Limited
31.4. Merck & Co. Inc.
31.5. Sumitomo Dainippon Pharma Co. Ltd.
31.6. China National Pharmaceutical Group Co. Ltd. (Sinopharm)
31.7. Shanghai Acebright Pharmaceuticals Group Co. Ltd.
31.8. Jiangsu Hengrui Medicine Co. Ltd
31.9. Hanmi Pharmaceutical
31.10. Cipla Limited
31.11. Aurobindo Pharma Limited
31.12. KYORIN Holdings Inc.
31.13. Nichi-Iko Pharmaceutical Co. Ltd.
31.14. Otsuka Pharmaceutical Co. Ltd.
31.15. Daewoong Pharmaceutical Co. Ltd

32. Global Anti-Asthmatics And COPD Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anti-Asthmatics And COPD Drugs Market

34. Recent Developments In The Anti-Asthmatics And COPD Drugs Market

35. Anti-Asthmatics And COPD Drugs Market High Potential Countries, Segments and Strategies

35.1 Anti-Asthmatics And COPD Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Anti-Asthmatics And COPD Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Anti-Asthmatics And COPD Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer